Campbell & Co Investment Adviser’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,602
| Closed | -$681K | – | 1202 |
|
|
2026
Q1 | $681K | Buy |
+3,602
| New | +$630K | 0.04% | 646 |
|
|
2025
Q2 | – | Sell |
-29,592
| Closed | -$3.67M | – | 1286 |
|
|
2025
Q1 | $3.67M | Buy |
+29,592
| New | +$3.86M | 0.28% | 70 |
|
|
2024
Q4 | – | Sell |
-11,945
| Closed | -$1.33M | – | 1201 |
|
|
2024
Q3 | $1.33M | Buy |
11,945
+3,557
| +42% | +$390K | 0.1% | 328 |
|
|
2024
Q2 | $895K | Buy |
8,388
+4,975
| +146% | +$547K | 0.08% | 407 |
|
|
2024
Q1 | $411K | Sell |
3,413
-7,765
| -69% | -$951K | 0.04% | 789 |
|
|
2023
Q4 | $1.37M | Buy |
11,178
+414
| +4% | +$51.7K | 0.12% | 250 |
|
|
2023
Q3 | $1.39M | Buy |
10,764
+8,078
| +301% | +$1.08M | 0.17% | 169 |
|
|
2023
Q2 | $333K | Buy |
+2,686
| New | +$361K | 0.06% | 617 |
|
|
2023
Q1 | – | Sell |
-8,041
| Closed | -$1.28M | – | 922 |
|
|
2022
Q4 | $1.28M | Sell |
8,041
-794
| -9% | -$116K | 0.31% | 52 |
|
|
2022
Q3 | $1.18M | Buy |
8,835
+4,118
| +87% | +$626K | 0.27% | 94 |
|
|
2022
Q2 | $736K | Buy |
+4,717
| New | +$726K | 0.2% | 155 |
|
|
2021
Q4 | – | Sell |
-4,491
| Closed | -$585K | – | 714 |
|
|
2021
Q3 | $585K | Buy |
+4,491
| New | +$679K | 0.19% | 170 |
|
|
2020
Q1 | – | Sell |
-1,494
| Closed | -$223K | – | 270 |
|
|
2019
Q4 | $223K | Sell |
1,494
-3,518
| -70% | -$479K | 0.07% | 542 |
|
|
2019
Q3 | $642K | Buy |
+5,012
| New | +$672K | 0.24% | 108 |
|
|
2019
Q2 | – | Sell |
-2,124
| Closed | -$304K | – | 610 |
|
|
2019
Q1 | $304K | Buy |
+2,124
| New | +$277K | 0.15% | 269 |
|
|
2018
Q4 | – | Sell |
-1,567
| Closed | -$263K | – | 415 |
|
|
2018
Q3 | $263K | Buy |
+1,567
| New | +$269K | 0.18% | 265 |
|
|
2016
Q3 | – | Sell |
-1,822
| Closed | -$257K | – | 165 |
|
|
2016
Q2 | $257K | Buy |
+1,822
| New | +$269K | 1.3% | 30 |
|
|
2015
Q4 | – | Sell |
-2,755
| Closed | -$366K | – | 149 |
|
|
2015
Q3 | $366K | Buy |
+2,755
| New | +$474K | 0.24% | 150 |
|
|
2015
Q1 | – | Sell |
-5,500
| Closed | -$901K | – | 238 |
|
|
2014
Q4 | $901K | Buy |
+5,500
| New | +$913K | 0.55% | 64 |
|
|
2014
Q1 | – | Sell |
-9,192
| Closed | -$1.16M | – | 249 |
|
|
2013
Q4 | $1.16M | Buy |
+9,192
| New | +$951K | 0.26% | 117 |
|
Other funds holding JAZZ
Campbell & Co Investment Adviser's JAZZ Position: Q2 2026 in Review
Campbell & Co Investment Adviser sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 3,602 shares — an estimated $681K sold.
Campbell & Co Investment Adviser first reported a position in JAZZ in Q4 2013 and held it in 20 quarters. The position peaked at $3.67M in Q1 2025. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Campbell & Co Investment Adviser reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Campbell & Co Investment Adviser sold 3,602 Jazz Pharmaceuticals shares in Q2 2026, an estimated $681K.
- Campbell & Co Investment Adviser first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 20 quarters.
- Campbell & Co Investment Adviser's Jazz Pharmaceuticals position peaked at $3.67M in Q1 2025.
- 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.